Clinical presentation and outcome of 30 patients with ATV-associated urolithiasis.

<p>Clinical presentation and outcome of 30 patients with ATV-associated urolithiasis.</p

Baseline characteristics of HIV-infected patients with atazanavir-associated urolithiasis and controls.

<p>Baseline characteristics of HIV-infected patients with atazanavir-associated urolithiasis and controls.</p

Risk factors for atazanavir-associated urolithiasis, univariate analysis.

<p>Risk factors for atazanavir-associated urolithiasis, univariate analysis.</p

Risk factors for atazanavir-associated urolithiasis, multivariate analysis.

<p>Risk factors for atazanavir-associated urolithiasis, multivariate analysis.</p

Longitudinal follow-up of HIV-1 DNA level during the ANRS 139 TRIO Trial.

<p>Longitudinal follow-up of HIV-1 DNA level during the ANRS 139 TRIO Trial.</p

Neutralization potency and breadth of HIV-1 patient #48 against a small panel of different HIV-1 viruses including clades AE, B, C, and E.

<p>Polyclonal inhibitory concentration of purified IgG fractions</p

Patient characteristics and results of antibody assays.

<p>Patient characteristics and results of antibody assays.</p

Comparison of HIV-1 specific antibody endpoint titers and time with detectable HIV RNA categorized as ≤10 and >10 years.

<p>Scatter plots of antibody endpoint titers to recombinant gp120_JR-FL, gp120_JR-FL ΔV1/V2, gp120_JR-FL ΔV3, and gp41 categorized by time with detectable HIV RNA show significantly higher titers for patients with >10 years of detectable viremia.</p

Summary of patients with neutralizing activity against HIV-1_JR-FL and/or HIV-2/HIV-1 7312-C1.

<p>Polyclonal inhibitory concentration of purified IgG fractions</p><p>^? Reciprocal dilution factor of serum samples</p

Comparison of HIV-1 specific antibody endpoint titers and time with HIV RNA<50 copies/mL categorized as ≤5 and >5 years.

<p>Median binding titers against gp120_JR-FL (A) and gp41_JR-FL (B) were both lower in patients with >5 years of undetectable viremia.</p